Janumet 850mg + 50mg #56

Janumet instruction for use

You can buy Janumet here

Composition

In one tablet, depending on the dosage of the drug, it can contain:
    500 mg of metformin and 50 mg of sitagliptin monohydrate phosphate;
    850 mg of metformin and 50 mg of sitagliptin monohydrate phosphate;
    1000 mg metformin and 50 mg phosphate monohydrate sitagliptin.
As auxiliary inactive substances, microcrystalline cellulose, povidone, sodium stearyl fumarate and sodium lauryl sulfate are used.
Opadry II shell pink 85 F 94203 consists of polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, iron oxide black (E172) and iron oxide red (E172).

Form of issue

Janumet is produced in coated tablets in the form of a film shell. Tablets are packed in aluminum or PVC blisters for 14 pcs. In a cardboard bundle there are 1, 2, 4, 6, 7 blisters.

pharmachologic effect

Hypoglycemic.

Pharmacodynamics and pharmacokinetics

The drug Janumet is a combination of two hypoglycemic substances with a complementary (complementary) mechanism of action. It was developed for better control of glycemia in patients with type II diabetes mellitus. By its nature, sitagliptin is an inhibitor of dipeptidyl peptidase-4 (abbreviated as DPP-4), whereas metformin is a representative of the biguanide class.
The pharmacological action of sitagliptin as an inhibitor of DPP-4 is mediated by the activation of incretins. When DPP-4 is inhibited, the concentration of the 2 active hormones of the family increases. incretins: glucagon-like peptide-1 (GLP-1), as well as a glucose-dependent insulinotropic polypeptide (GIP). These hormones are part of the internal physiological system regulating glucose homeostasis. If the blood glucose level is normal or elevated, the above incretins contribute to an increase in the synthesis of insulin and its secretion. In addition, GLP-1 suppresses the release of glucagon, which suppresses the process of glucose synthesis in the liver. Sitagliptin in therapeutic doses does not inhibit the activity of enzymes-dipeptidyl peptidase-8 and dipeptidyl peptidase-9.
By increasing glucose tolerance in patients with type II diabetes by metformin, basal and postprandial glucose concentrations in the blood stream decrease. In addition, there is a decrease in glucose synthesis in the liver (gluconeogenesis), glucose absorption in the intestine is reduced, insulin sensitivity is increased due to the capture and utilization of glucose molecules. Its pharmacological mechanism of action differs from other oral hypoglycemic agents of other classes.

Indications for use

The drug Janumet is shown as an addition to the regime of physical activity and diet, contributing to better control of glycemia in type II diabetes mellitus. Treatment can also be carried out in combination:
    with preparations, active substances of which are derivatives of sulfonylureas (a combination of 3 drugs);
    with PPAR agonists (eg, thiazolidinediones);
    with insulin.

Contraindications

    hypersensitivity to any of the components of Janumet;
    severe conditions that can affect kidney function, such as shock, dehydration, infection;
    acute / chronic forms of diseases leading to tissue hypoxia: cardiac, respiratory failure, recent myocardial infarction;
    moderate or severe disorders of the kidneys, liver;
    the state of acute alcohol intoxication or a disease such as alcoholism;
    diabetes mellitus type I;
    acute or chronic metabolic acidosis, including diabetic ketoacidosis;
    radiological research;
    pregnancy and lactation.

Side effects

    headache;
    drowsiness;
    cough;
    nausea, abdominal pain;
    diarrhea, constipation;
    dry mouth;
    vomiting;
    pancreatitis;
    peripheral edema.

Instruction on Janumet (Method and dosage)

Tablets Janumet take two meals a day during meals. To minimize possible side effects from the gastrointestinal tract, the dose is increased in stages. The initial dose is selected depending on the current stage of hypoglycemic therapy.
In the instruction for the use of Janumet, the maximum daily dose of sitagliptin is 100 mg.
Attention! The dosage regimen of the hypoglycemic preparation Janumet must be selected individually, taking into account the current therapy, its effectiveness and tolerability.

Overdose

When taking over the dose of Janumet, it is recommended to perform standard measures first: remove the remains of unabsorbed drug from the digestive tract, monitor vital signs (ECG), conduct hemodialysis and prescribe supportive therapy if necessary.

Interaction

There were no studies of drug-to-drug interaction between the preparation of Janumet, but enough research was carried out for each active ingredient, sitagliptin and metformin.
    Sitagliptin when interacting with other drugs causes an increase in AUC, maximum concentration (C max) of Digoxin, Januvia, Cyclosporine, however these pharmacokinetic changes are not considered clinically significant.
    A single dose of Furosemide leads to an increase in Cmax of metformin and AUC in plasma and blood by approximately 22% and 15%, respectively, whereas C max and Furosemide AUC decreased.
    After taking Nifedipine, C max of metformin is increased by 20% and AUC by 9%.

Storage conditions

The temperature does not exceed + 25 ° Celsius.
For safety reasons, access to children should be restricted.

Shelf life

Do not use after two years.

Reviews about Janumet

Reviews about Janumet on the forums say that this is the best drug for the treatment of type 2 diabetes. It has high efficiency and no side effects.